SCILEX HOLDING CO (SCLX) Stock Price, Quote, News and Overview
NASDAQ:SCLX - Nasdaq - US80880W1062 - Common Stock - Currency: USD
SCLX Quote, Performance and Key Statistics
0.3298
-0.01 (-1.7%)
The current stock price of SCLX is 0.3298 USD. In the past month the price decreased by -23.3%. In the past year, price decreased by -81.15%.
SCLX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About SCLX
Company Profile
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. The company is headquartered in Palo Alto, California and currently employs 113 full-time employees. The company went IPO on 2021-01-11. The firm's commercial product, ZTlido (lidocaine topical system) 1.8%, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. The company also focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. Its second commercial product ELYXYB, is a potential first-line treatment, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. Its product candidates include SP-102 (SEMDEXA), SP-103 and SP-104. SP-102 is a viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica. Its SP-103 is a triple-strength formulation of ZTlido, for the treatment of chronic neck pain.
Company Info
SCILEX HOLDING CO
960 San Antonio Road
Palo Alto CALIFORNIA US
Employees: 113
Company Website: https://www.scilexholding.com/
Investor Relations: http://www.scilexholding.com/investors/overview/
Phone: 16505164310
SCILEX HOLDING CO / SCLX FAQ
What is the stock price of SCILEX HOLDING CO today?
The current stock price of SCLX is 0.3298 USD. The price decreased by -1.7% in the last trading session.
What is the ticker symbol for SCILEX HOLDING CO stock?
The exchange symbol of SCILEX HOLDING CO is SCLX and it is listed on the Nasdaq exchange.
On which exchange is SCLX stock listed?
SCLX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SCILEX HOLDING CO stock?
10 analysts have analysed SCLX and the average price target is 10.86 USD. This implies a price increase of 3193.81% is expected in the next year compared to the current price of 0.3298. Check the SCILEX HOLDING CO stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SCILEX HOLDING CO worth?
SCILEX HOLDING CO (SCLX) has a market capitalization of 80.24M USD. This makes SCLX a Micro Cap stock.
How many employees does SCILEX HOLDING CO have?
SCILEX HOLDING CO (SCLX) currently has 113 employees.
What are the support and resistance levels for SCILEX HOLDING CO (SCLX) stock?
SCILEX HOLDING CO (SCLX) has a resistance level at 0.36. Check the full technical report for a detailed analysis of SCLX support and resistance levels.
Is SCILEX HOLDING CO (SCLX) expected to grow?
The Revenue of SCILEX HOLDING CO (SCLX) is expected to grow by 27.26% in the next year. Check the estimates tab for more information on the SCLX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SCILEX HOLDING CO (SCLX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SCLX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SCLX, evaluating the profitability, health, valuation and growth aspects
- SCILEX HOLDING CO (SCLX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SCILEX HOLDING CO (SCLX) Sales and EPS estimates to see what analysts future expectations are.
- SCILEX HOLDING CO (SCLX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SCILEX HOLDING CO (SCLX) Insider and Institutional Ownership to learn about the owners and their transactions.
- SCILEX HOLDING CO (SCLX) Stock Chart to make your own analysis
- SCILEX HOLDING CO (SCLX) Latest news and press-releases to stay up to date.
Does SCILEX HOLDING CO (SCLX) stock pay dividends?
SCLX does not pay a dividend.
What is the Price/Earnings (PE) ratio of SCILEX HOLDING CO (SCLX)?
SCILEX HOLDING CO (SCLX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.25).
What is the Short Interest ratio of SCILEX HOLDING CO (SCLX) stock?
The outstanding short interest for SCILEX HOLDING CO (SCLX) is 2.41% of its float. Check the ownership tab for more information on the SCLX short interest.
SCLX Technical Analysis
SCLX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SCLX. Both the profitability and financial health of SCLX have multiple concerns.
SCLX Financial Highlights
Over the last trailing twelve months SCLX reported a non-GAAP Earnings per Share(EPS) of -1.25. The EPS decreased by -1838.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -164.82% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SCLX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to SCLX. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 33.75% and a revenue growth 27.26% for SCLX